MK-0767
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- MK-0767
- DrugBank Accession Number
- DB12055
- Background
MK0767 has been used in trials studying the treatment of Dyslipidemia, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, and Diabetes Mellitus, Type II, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 422.36
Monoisotopic: 422.108956144 - Chemical Formula
- C20H17F3N2O5
- Synonyms
- Not Available
- External IDs
- MK 0767
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-benzylbenzamides. These are compounds containing a benzamide moiety that is N-linked to a benzyl group.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- N-benzylbenzamides
- Alternative Parents
- Trifluoromethylbenzenes / Anisoles / Benzoyl derivatives / Methoxybenzenes / Phenoxy compounds / Alkyl aryl ethers / Oxazolidinediones / Dicarboximides / Carbamate esters / Secondary carboxylic acid amides show 8 more
- Substituents
- Alkyl aryl ether / Alkyl fluoride / Alkyl halide / Anisole / Aromatic heteromonocyclic compound / Azacycle / Benzoyl / Carbamic acid ester / Carbonyl group / Carboxamide group show 22 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Y180U02GSB
- CAS number
- 934017-32-0
- InChI Key
- ORZMUVMQJPGFOM-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H17F3N2O5/c1-29-15-7-4-12(9-16-18(27)25-19(28)30-16)8-14(15)17(26)24-10-11-2-5-13(6-3-11)20(21,22)23/h2-8,16H,9-10H2,1H3,(H,24,26)(H,25,27,28)
- IUPAC Name
- 5-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]-2-methoxy-N-{[4-(trifluoromethyl)phenyl]methyl}benzamide
- SMILES
- COC1=CC=C(CC2OC(=O)NC2=O)C=C1C(=O)NCC1=CC=C(C=C1)C(F)(F)F
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Terminated Treatment Diabetes Mellitus 1 3 Terminated Treatment Dyslipidemia / Type 2 Diabetes Mellitus 1 3 Terminated Treatment Type 2 Diabetes Mellitus 6 2 Terminated Treatment Metabolic X Syndrome Dyslipidemia 1 2 Terminated Treatment Type 2 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00458 mg/mL ALOGPS logP 2.53 ALOGPS logP 3.02 Chemaxon logS -5 ALOGPS pKa (Strongest Acidic) 6.63 Chemaxon pKa (Strongest Basic) -1.4 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 93.73 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 99.23 m3·mol-1 Chemaxon Polarizability 38.43 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-0130900000-21d1c19799850eb37d97 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00du-5419300000-2533e9a4d2afb01cdc6b Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0udj-0349100000-ea20e610268b02bc508f Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9324000000-c78febf30171057cd43b Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0uea-0933000000-6c511cc24547b1a69478 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-6209100000-f430a418e0950a6684b2 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 186.75877 predictedDeepCCS 1.0 (2019) [M+H]+ 189.11678 predictedDeepCCS 1.0 (2019) [M+Na]+ 195.47208 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 21:16 / Updated at June 12, 2020 16:53